Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, has announced an agreement to acquire the specialized pharmaceutical manufacturer NewCo Pharma GmbH ("NewCo Pharma"), based in Mannheim.
The purchase price includes a cash component amounting to EUR 85.2 million and 924,233 newly issued Medios shares, which are subject to a lock-up period of 12 months (50%) and 24 months (50%).
The acquisition is subject to approval by the German Federal Cartel Office, with the transaction expected to close in the first quarter of 2022.
About NewCo Pharma
The NewCo Pharma Group is a national network of five regional manufacturing and wholesale companies focused on northern, western, and southern Germany. It specializes in producing patient-specific infusion solutions for specialized pharmacies. In 2020, NewCo Pharma achieved a turnover of EUR 153 million and an EBITDA of approximately EUR 13 million.
About Medios AG
Medios is Germany's leading provider of Specialty Pharma Solutions, covering all aspects of the supply chain, from the supply of medicines to the production of patient-specific therapies, including blister packaging. Medios focuses on optimal patient care through specialized pharmacies.
Medios is Germany's first listed specialty pharmaceutical company, with shares (ISIN: DE000A1MMCC8) listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard).
Medios aims to generate sales of over EUR 1.5 billion in 2022, together with NewCo Pharma, and to increase profit margins to well over 3%. The integration of NewCo Pharma's production capacities is expected to nearly triple the production of tailored infusion solutions and other parenterals, expanding to over 300,000 productions in the 2022 financial year. Additionally, the acquisition will create synergies in purchasing and in the area of clinical trials and study medication. The management of NewCo Pharma sees significant growth opportunities within Medios AG and will continue to support the joint group of companies.
ConAlliance is a leading M&A advisory firm specializing in comprehensive support for company sales and acquisitions within the healthcare sector. Since its founding in 2011, ConAlliance has successfully managed over 150 mandates.
ConAlliance's expertise is highly focused on corporate transactions within the healthcare sector. In addition to the pharmaceutical industry, ConAlliance's core competencies include hospitals, nursing, healthcare IT, medical technology, medical devices, and other manufacturing and service companies in the global healthcare industry, as well as healthcare real estate.
For more information about ConAlliance, please visit www.ConAlliance.com.